InnoCare Pharma (诺诚健华) signed a strategic R&D and licensing agreement with Eli Lilly, potentially receiving up to $100 million in upfront and near-term payments, plus up to $3.25 billion in development and commercialization milestones, and tiered single-digit royalties on annual net sales.
InnoCare's landmark deal with Eli Lilly is a major validation of its R&D capabilities, with multiple near-term catalysts that could drive the stock higher.
Free preview — more China A-share & HK research · About Us · Legal & Privacy